49 related articles for article (PubMed ID: 7679595)
21. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases.
Robbins SG; Mixon RN; Wilson DJ; Hart CE; Robertson JE; Westra I; Planck SR; Rosenbaum JT
Invest Ophthalmol Vis Sci; 1994 Sep; 35(10):3649-63. PubMed ID: 8088954
[TBL] [Abstract][Full Text] [Related]
22. Localisation of opticin in human proliferative retinal disease.
Pattwell DM; Sheridan CM; Le Goff M; Bishop PN; Hiscott P
Exp Eye Res; 2010 Mar; 90(3):461-4. PubMed ID: 20036236
[TBL] [Abstract][Full Text] [Related]
23. Indicators of oxidative tissue damage and inflammatory activity in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Augustin AJ; Spitznas M; Koch F; Grus F; Böker T
Ger J Ophthalmol; 1995 Jan; 4(1):47-51. PubMed ID: 7728110
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
25. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
[TBL] [Abstract][Full Text] [Related]
26. Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy.
Hagedorn M; Esser P; Wiedemann P; Heimann K
Ger J Ophthalmol; 1993 Feb; 2(1):28-31. PubMed ID: 7679595
[TBL] [Abstract][Full Text] [Related]
27. [The role of cellular adhesion molecule in the development of proliferative diabetic retinopathy].
Adamiec J; Oficjalska-Młyńczak J
Klin Oczna; 2005; 107(4-6):330-3. PubMed ID: 16118951
[TBL] [Abstract][Full Text] [Related]
28. [Proliferative vitreoretinopathy: new discoveries in pathophysiology and therapy].
Wiedemann P; Weller M; Heimann K
Klin Monbl Augenheilkd; 1990 Nov; 197(5):355-61. PubMed ID: 2290290
[TBL] [Abstract][Full Text] [Related]
29. Inflammation and the formation of epiretinal membranes.
Gilbert C; Hiscott P; Unger W; Grierson I; McLeod D
Eye (Lond); 1988; 2 Suppl():S140-56. PubMed ID: 3076143
[TBL] [Abstract][Full Text] [Related]
30. Periostin in vitreoretinal diseases.
Yoshida S; Nakama T; Ishikawa K; Nakao S; Sonoda KH; Ishibashi T
Cell Mol Life Sci; 2017 Dec; 74(23):4329-4337. PubMed ID: 28913545
[TBL] [Abstract][Full Text] [Related]
31. Minireview: Fibronectin in retinal disease.
Miller CG; Budoff G; Prenner JL; Schwarzbauer JE
Exp Biol Med (Maywood); 2017 Jan; 242(1):1-7. PubMed ID: 27798121
[TBL] [Abstract][Full Text] [Related]
32. Syndecan--a cell surface proteoglycan that selectively binds extracellular effector molecules.
Jalkanen M; Elenius K; Salmivirta M
Adv Exp Med Biol; 1992; 313():79-85. PubMed ID: 1279953
[No Abstract] [Full Text] [Related]
33. Mononuclear phagocytes in proliferative vitreoretinopathy (PVR). A specific role of microglial cells in non-traumatic disease?
Weller M; Esser P; Heimann K; Wiedemann P
Eur J Ophthalmol; 1991; 1(4):161-6. PubMed ID: 1821209
[TBL] [Abstract][Full Text] [Related]
34. Immune responses to injury and their links to eye disease.
Stepp MA; Menko AS
Transl Res; 2021 Oct; 236():52-71. PubMed ID: 34051364
[TBL] [Abstract][Full Text] [Related]
35. Extracellular matrix remodeling during retinal development.
Reinhard J; Joachim SC; Faissner A
Exp Eye Res; 2015 Apr; 133():132-40. PubMed ID: 25017186
[TBL] [Abstract][Full Text] [Related]
36. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration.
Wiedemann P
Surv Ophthalmol; 1992; 36(5):373-84. PubMed ID: 1566240
[TBL] [Abstract][Full Text] [Related]
37. [Cytokines and their role in pathogenesis of diabetic retinopathy].
Tret'iak EB; Syroedova ON; Neuhaus O; Andreeva AV; Antsiferov MB; Mkrtumian AM; Suchkov SV
Vestn Oftalmol; 2010; 126(6):53-7. PubMed ID: 21395004
[TBL] [Abstract][Full Text] [Related]
38. Syndecan and tenascin: induction during early tooth morphogenesis and possible interactions.
Thesleff I; Vainio S; Salmivirta M; Jalkanen M
Cell Differ Dev; 1990 Dec; 32(3):383-9. PubMed ID: 1711918
[No Abstract] [Full Text] [Related]
39. Periostin in Eye Diseases.
Yoshida S; Umeno Y; Haruta M
Adv Exp Med Biol; 2019; 1132():113-124. PubMed ID: 31037630
[TBL] [Abstract][Full Text] [Related]
40. A role for excitatory amino acids in diabetic eye disease.
Pulido JE; Pulido JS; Erie JC; Arroyo J; Bertram K; Lu MJ; Shippy SA
Exp Diabetes Res; 2007; 2007():36150. PubMed ID: 17713594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
